Metabolites released from apoptotic cells act as novel tissue messengers

Christopher B. Medina\(^1,2\), *Parul Mehrotra\(^7\), *Sanja Arandjelovic\(^1,2\), *Justin S.A. Perry\(^1,2\), Yizhan Guo\(^3\), Sho Morioka\(^1,2\), Brady Barron\(^1,5\), Scott F. Walk\(^1,2\), Bart Ghesquière\(^6\), Alexander S. Krupnick\(^3,5\), Ulrike Lorenz\(^2,6\), and Kodi S. Ravichandran\(^{1,2,4,6,7}\)

\(^1\)Center for Cell Clearance, \(^2\)Department of Microbiology, Immunology, and Cancer Biology, \(^3\)Department of Surgery, \(^4\)Pharmacology, and \(^5\)Carter Immunology Center, University of Virginia, Charlottesville, VA, \(^6\)Department of Oncology and VIB, KULeuven, Belgium, and \(^7\)VIB/UGent Inflammation Research Centre, Biomedical Molecular Biology, Ghent University, Belgium. * contributed equally to this work
**Supplementary Table 1. Jurkat UV metabolite release.** List of metabolites released after UV treatment of Jurkat cells relative to live cell controls (n=4). Two-sided Welch’s two-sample t-test.

**Supplementary Table 2. Metabolite supernatant enrichment and pellet decrease.** List of metabolites released after UV treatment of Jurkat cells relative to live cell controls (n=4) and reciprocally decreased in the cell pellet (n=4).

**Supplementary Table 3. HMT metabolites.** List of metabolites screened in the targeted metabolomics analysis.

**Supplementary Table 4.** Table of metabolites released in a Panx1-dependent manner from untargeted metabolomics of Jurkat T cells undergoing apoptosis. Along with metabolite name, metabolite size (in Daltons), charge, and reference to previous studies, where particular extracellular treatment of the specific metabolites have been attempted.

**References related to Supplementary Table 4.**